NASDAQ OMX

FutureWAN'18 Brings Industry Leaders Together for Global SD-WAN Summit

Dela

Amazon Web Services, IDC, Cisco and ServiceNow Among Featured Presenters

 

SAN JOSE, Calif., Jan. 18, 2018 (GLOBE NEWSWIRE) -- The FutureWAN'18 Summit today announced keynote presenters and the full agenda for its four day virtual summit. The global SD-WAN summit will feature analysts, technology providers, enterprise IT users and service providers. FutureWAN'18 will share experiences and deliver comprehensive education on the major aspects of enterprise WAN problems. Running Jan. 23 through Jan 26, the virtual event will feature multiple tracks, including Cloud, Security, Enterprise SD-WAN (Operations) and Managed Services.

SD-WAN's growth has created new and exciting growth opportunities for service providers and cloud players. The FutureWAN'18 summit will feature presentations by key players, including Verizon, BT, Orange Business Services and Amazon Web Services, among others, that are taking advantage of this new frontier. In addition, the summit will feature analyst presentations by IDC, Packet Pushers, Global Data, GestaltIT and EMA Research.

"Cloud adaption has made SD-WAN an important factor in network transformation decisions," stated Shamus McGillicuddy, Senior Analyst at EMA. "Enterprises require a modernized, cloud-ready infrastructure on which to roll out the new applications with enterprise-wide monitoring and control. SD-WAN delivers on many of those requirements." 

"Responding to the limitations of traditional WAN architectures and to the operational inefficiencies of legacy WAN management, software-defined WAN (SD-WAN) has struck a responsive chord with enterprises across a broad array of industries," said Brad Casemore, Research Director, Datacenter Networking at IDC. "Indeed, as the SD-WAN market moves into its next stage of robust growth - driven by mainstream enterprise adoption - IDC expects to see significant innovations during the next few years that will ensure that SD-WAN provides even greater value to enterprises worldwide."

The web-delivered summit is free for registered attendees. For a full schedule and to register visit: https://vshow.on24.com/vshow/sdwan/registration/14922

Summit Tracks: Jan. 23 - 26, 2018
Cloud Transformation

  • EMA Research: Establishing a Path to the Cloud-Ready Network with SD-WAN
  • Cisco: Solving Office 365 and SaaS Performance Issues with SD-WAN
  • Amazon Web Services: Extending VPCs with Cisco SD-WAN
  • Cisco: Speeding Amazon Web Services/Azure Migrations with SD-WAN
  • SD-WAN Demo: Application SLA Policies, Public Cloud and SaaS

Enterprise SD-WAN

  • Voice of the Customer: Retail Store Transformation with SD-WAN
  • ServiceNow: Delivering Efficient Service Management Capabilities with SD-WAN Alarms
  • Packet Pushers: State of SD-WAN, Q&A
  • Cisco: What to Ask Your Vendor - The Essential SD-WAN Capabilities?
  • SD-WAN Demo: Stepwise Migration from MPLS to Hybrid

Security and Branch Services

  • Voice of the Customer: Healthcare Transformation with SD-WAN
  • IDC: The Next Wave of SD-WAN Transformation, Research and Predictions
  • GestaltIT: Network Architect Roundtable: Best Practices on SD-WAN Migration
  • Cisco: Securing Branches with Secure Internet Gateways (SIG) and SD-WAN
  • SD-WAN Demo: Segmentation, the Most Implemented SD-WAN Feature

Managed Services

  • BT: Enabling Global Digital Transformation
  • Global Data: Managing Service Up the Value Chain with SD-WAN
  • Verizon: Case Studies in Managed SD-WAN Deployments
  • Orange Business Services: Speeding Transformation with Managed SD-WAN

About FutureWAN'18
FutureWAN'18 brings together network architects, industry analysts, telecom carriers and leading technology providers to discuss the next wave of SD-WAN deployments. The four day virtual summit will feature four tracks: enterprise SD-WAN, security and branch services, cloud transformation and managed services. Speakers will provide a comprehensive industry view on the requirements, best practices and lessons learned in migrating to SD-WAN. The views and opinions expressed by the speakers who are not employed by Cisco or associated with Cisco do not represent or reflect the views of Cisco or Cisco's affiliates. For more information, visit https://vshow.on24.com/vshow/sdwan/registration/14922.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/cc848d32-247c-4941-a868-b93d2a91861b

PR Contact:
Taylor Hassman
415-610-6075
thassman@cisco.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Cisco via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Karolinska Development's portfolio company Asarina Pharma is listed on Nasdaq First North24.9.2018 08:00Pressmeddelande

STOCKHOLM, 24 September 2018. Karolinska Development's portfolio company Asarina Pharma will today be listed on Nasdaq First North in Stockholm. In connection with the listing, Asarina Pharma is issuing 6.8 million shares. The issue price of SEK 21 gives Asarina Pharma a pre money valuation of SEK 172 million. Conditioned that the over-allotment option of an additional 0.35 million shares is fully exercised, Asarina Pharma will be provided with a total of SEK 150.2 million before issue costs. Asarina Pharma is a Swedish biotech company focused on chronic diseases associated with the menstrual cycle. The portfolio company is developing the drug candidate sepranolone as a treatment for premenstrual dysphoric disorder (PMDD) and premenstrual migraine. A Phase IIb study is currently underway in PMDD with expected completion by the end of 2019. Furthermore, Asarina Pharma is planning a clinical Phase IIa study in menstrual migraine for the first half of 2019. Karolinska Development is a pas

Karolinska Development's portfolio company Asarina Pharma is listed on Nasdaq First North24.9.2018 08:00Pressmeddelande

STOCKHOLM, 24 September 2018. Karolinska Development's portfolio company Asarina Pharma will today be listed on Nasdaq First North in Stockholm. In connection with the listing, Asarina Pharma is issuing 6.8 million shares. The issue price of SEK 21 gives Asarina Pharma a pre money valuation of SEK 172 million. Conditioned that the over-allotment option of an additional 0.35 million shares is fully exercised, Asarina Pharma will be provided with a total of SEK 150.2 million before issue costs. Asarina Pharma is a Swedish biotech company focused on chronic diseases associated with the menstrual cycle. The portfolio company is developing the drug candidate sepranolone as a treatment for premenstrual dysphoric disorder (PMDD) and premenstrual migraine. A Phase IIb study is currently underway in PMDD with expected completion by the end of 2019. Furthermore, Asarina Pharma is planning a clinical Phase IIa study in menstrual migraine for the first half of 2019. Karolinska Development is a pas

Immunicum AB (publ) meddelar att Pawel Kalinski och Inge Marie Svane har valts in i det vetenskapliga rådet17.9.2018 08:00Pressmeddelande

Pressmeddelande 17 september 2018 Immunicum AB (publ) meddelar att Pawel Kalinski och Inge Marie Svane har valts in i det vetenskapliga rådet Immunicum AB (publ; IMMU.ST) meddelade i dag att två ledande immun-onkologiska experter har valts in i bolagets vetenskapliga råd för att fungera som strategiska resurser för Immunicum under bolagets fortsatta kliniska utveckling av sin ledande produkt, ilixadencel. Pawel Kalinski, MD, PhD, vice ordförande för translationell forskning vid den medicinska institutionen vid Roswell Park Comprehensive Cancer Center, och Inge Marie Svane, MD, PhD, professor, chef för det kliniska cancerforskningsprogrammet på medicinska fakulteten vid Köpenhamns universitet, chef för Center för cancerimmunterapi (CCIT) samt överläkare inom onkologi, Herlevs universitetssjukhus har valts in i rådet. - Vi är hedrade att ha experter med specialistkompetens inom området immunonkologi och cellterapi i vårt vetenskapliga råd, vilka kan erbjuda ytterligare vägledning när det

Immunicum AB (publ) Announces Appointment of Pawel Kalinski and Inge Marie Svane to Scientific Advisory Board17.9.2018 08:00Pressmeddelande

Press Release 17 September 2018 Immunicum AB (publ) Announces Appointment of Pawel Kalinski and Inge Marie Svane to Scientific Advisory Board Immunicum AB (publ; IMMU.ST) announced today the appointment of leading oncology experts to its Scientific Advisory Board with the addition of Pawel Kalinski, MD, PhD, Vice Chair for Translational Research within the Department of Medicine at Roswell Park Comprehensive Cancer Center, and Inge Marie Svane, MD, PhD, Professor, Head of the Clinical Cancer Research programme, Faculty of Health Sciences, University of Copenhagen, Director, Centre for Cancer Immunotherapy (CCIT), and consultant in Oncology, Herlev University Hospital. Both Scientific Advisory Board members will serve as a strategic resource to Immunicum as the company continues to advance the clinical development of its lead product, ilixadencel. "We are honored to have such highly specialized experts in the field of immuno-oncology and cell therapy join our Scientific Advisory Board a

Hoylu AB: HOYLU HIRES NEW CTO, SATOSHI NAKAJIMA AND ANNOUNCES EXPANSION INTO JAPAN14.9.2018 08:30Pressmeddelande

Malmo, Sweden, September 14, 2018 - Hoylu, a leading enterprise collaboration company, announced today Satoshi Nakajima will join Hoylu in the newly created position, as Chief Technology Officer and President of Hoylu Japan. Nakajima will guide the strategic technology direction and innovation of Hoylu while also leading the new Hoylu office in Tokyo, Japan. "Satoshi is a visionary and world-class technologist who has substantial experience in delivering world class innovations. He is joining the Company as we are extending our reach and expanding into Japan," said Stein Revelsby, CEO. "Satoshi's extensive experience in strategy and delivering technology that support a great user experience will make an immediate impact on the company." Nakajima will serve as President of Hoylu Japan and will report to Stein Revelsby. His leadership will strengthen customer relations and help develop new business among emerging and established Japanese companies while strengthening the global position

Hoylu AB: HOYLU ANSTÄLLER SATOSHI NAKAJIMA SOM NY CTO OCH EXPANDERAR TILL JAPAN14.9.2018 08:30Pressmeddelande

Malmö, Sverige, 14 september 2018 - Hoylu, ett ledande företag inom samarbetsmjukvara för företagsmarknaden annonserar idag att Satoshi Nakajima tar anställning som CTO (Chief Technology Officer) och President för Hoylu Japan. Nakajima kommer styra den strategiska inriktningen för företagets produkter och leda innovationsarbetet. Han kommer också leda Hoylus nyöppnade kontor i Tokyo, Japan. Satoshi är en visionär teknologiexpert som har stor erfarenhet av att skapa innovativa lösningar. Han kommer till Hoylu samtidigt som vi utökar marknaden till att även täcka in Japan säger Stein Revelsby, VD. "Satoshis långa och gedigna erfarenhet i strategiska frågor och tekniska lösningar med fokus på användarupplevelse kommer få stor betydelse för oss." Nakajima kommer även att bli President för Hoylu Japan och kommer rapportera till Stein Revelsby. Hans ledarskap kommer stärka existerande kundrelationer och utveckla nya affärer på den japanska marknaden och samtidigt bidra till att flytta fram p

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum